Last reviewed · How we verify
UCB7858
At a glance
| Generic name | UCB7858 |
|---|---|
| Sponsor | UCB Biopharma S.P.R.L. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (PHASE1, PHASE2)
- A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants (PHASE1)
- A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UCB7858 CI brief — competitive landscape report
- UCB7858 updates RSS · CI watch RSS
- UCB Biopharma S.P.R.L. portfolio CI